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Abstract
Background: New products evolving from research and development can only be translated to
medical practice on a large scale if they are reimbursed by third-party payers. Yet the decision
processes regarding reimbursement are highly complex and internationally heterogeneous. This
study develops a process-oriented framework for monitoring these so-called fourth hurdle
procedures in the context of product development from bench to bedside. The framework is
suitable both for new drugs and other medical technologies.
Methods: The study is based on expert interviews and literature searches, as well as an analysis
of 47 websites of coverage decision-makers in England, Germany and the USA.
Results: Eight key steps for monitoring fourth hurdle procedures from a company perspective
were determined: entering the scope of a healthcare payer; trigger of decision process; assessment;
appraisal; setting level of reimbursement; establishing rules for service provision; formal and
informal participation; and publication of the decision and supplementary information. Details are
given for the English National Institute for Health and Clinical Excellence, the German Federal Joint
Committee, Medicare's National and Local Coverage Determinations, and for Blue Cross Blue
Shield companies.
Conclusion: Coverage determination decisions for new procedures tend to be less formalized
than for novel drugs. The analysis of coverage procedures and requirements shows that the proof
of patient benefit is essential. Cost-effectiveness is likely to gain importance in future.
Background
There is a gap between scientific knowledge and daily
medical practice. While there have been major scientific
breakthroughs, e.g. in the field of genomics or stem cell
research, this does not necessarily directly translate into a
variety of new treatments available to patients. A term fre-
quently used to describe approaches for bridging this gap
is "translational medicine". Translational medicine faces
two major obstacles: the first is the translation of basic sci-
ence discoveries into clinical studies; the second is to
translate clinical studies into medical practice [1]. A large
body of literature has focused on the first aspect [2,3]. Yet
the second obstacle, which usually depends on coverage
by third-party payers, is also essential for the economic
success of new products in clinical development.
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Coverage determination may prove to be a hurdle as diffi-
cult as those encountered in demonstrating the product's
efficacy, safety and quality. Due to rapidly increasing
healthcare expenditures, numerous countries currently set
up institutions that further evaluate new medical technol-
ogies after their market approval, before national health
services or insurance systems provide coverage [4]. The so-
called fourth hurdle set up by third-party payers should
thus be considered by those who are involved with earlier
stages of medical innovation, e.g. when target conditions
and countries are selected and clinical trials are planned.
Looking closely at procedures for coverage determination
may demand more attention than a time-constraint clini-
cian or manager can give – the fourth hurdle is highly het-
erogeneous and subject to frequent reform. Earlier studies
have approached the fourth hurdle from a legal or institu-
tional perspective [5,6]. Yet these approaches are quite
complex and do not fit easily within the context of the
whole process of translation, frequently represented by
value-chain steps from basic research to application in
healthcare.
This study develops a process-oriented framework to
describe fourth hurdle procedures from the perspective of
a life sciences company. The framework fits into value-
chain representations of technology development and
allows for easy presentation and monitoring of these deci-
sion procedures. Guidance is derived on how to prepare in
advance for the later stages of translational medicine.
Methods
The study is based on expert interviews, as well as a litera-
ture search in PubMed, CRD, Econlit and generally via
Google. Relevant attributes of coverage decision-making
procedures were extracted and consolidated to a limited
number of categories, to fulfil the following, conflicting
targets to the highest possible degree:
￿ Small number, to be manageable
￿ Conclusive, to describe all items relevant to a life sci-
ences company
￿ Universal, to facilitate an international comparison of
procedures
￿ Accessible, to enable an investigation of these items for
a potential market.
The framework was developed as part of a research project
on coverage of novel tissue-engineering (TE) treatments
which investigated coverage and reimbursement proc-
esses for Autologous Chondrocyte Implantation (ACI) [7-
9]. ACI is a novel TE treatment for cartilage defects, partic-
ularly in knee joints. Small samples of normal cartilage
incorporating cartilage-producing cells (chondrocytes)
are removed from the damaged joint, cultured in special
laboratories, and re-implanted into the areas of cartilage
damage. While ACI may be an effective and cost-effective
treatment, the evidence of its long-term benefit is still
weak [10]. ACI is the first tissue-engineering treatment
that has been subject to explicit coverage decisions in Eng-
land, Germany and the USA. Most of the current literature
is dedicated to the coverage of novel drugs ([e.g.
[4,11,12]]), yet innovation in life sciences also encom-
passes other types of technologies such as procedures
applied in hospital. Given the variety of fourth hurdle
procedures, the fourth hurdle of these other technologies
may not be represented appropriately by procedures
aimed at dealing with new pharmaceuticals. The choice of
a tissue-engineering procedure as reference case allowed
for a framework that is also suitable for other areas of life
sciences innovation.
In order to cover various aspects of reimbursement deci-
sions for different types of healthcare funding, institutions
in England (tax-based), Germany (social health insur-
ance) and the USA (large share of private health insur-
ance) were chosen. These countries are of outstanding
importance to innovative life sciences companies due to
their large healthcare expenses. Decisions by the follow-
ing institutions were selected for comparison: for the Eng-
lish National Health Service, the National Institute for
Health and Clinical Excellence (NICE) was selected as the
NICE appraisals are relevant for the entire English popu-
lation and NICE serves as an international reference for
fourth hurdle institutions [13]. For Germany, the deci-
sions by the Federal Joint Committee ("Gemeinsamer
Bundesausschuss", G-BA) were investigated, which are rel-
evant to approximately 90% of the population who are
covered by the statutory health insurance. For the USA,
decisions by Medicare were investigated, as Medicare is
the largest publicly funded healthcare payer [14] and its
decisions strongly influence those of private payers [15].
Private health insurance and out-of-pocket payments
account for more than half of the total of USA healthcare
expenditures [16]. As an example of a private payer of sig-
nificant size, the companies of the Blue Cross Blue Shield
Association were included in the analysis. 44 websites of
different payers in the USA were searched [for details, see:
[8,9]].
The selected institutions are highly relevant to life sciences
companies due to the healthcare budget within the scope
of their decisions. They additionally represent very differ-
ent approaches to coverage determination. For this rea-
son, it is important to understand the coverage procedures
of these institutions before proceeding to a wider interna-
tional comparison.BMC Health Services Research 2008, 8:194 http://www.biomedcentral.com/1472-6963/8/194
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Institutions for coverage determination are frequently
subject to tight regulation and supervision by government
and social courts. This analysis is dedicated to decision-
making procedures within the institutions; the legal basis
and decisions shaping these institutions were excluded
from this analysis. Fourth hurdle procedures are indirectly
affected by the rigour of licensing decisions which can
vary by type of technology and by jurisdiction. Due to its
focus on reimbursement decision making, also the proce-
dures of market approval are beyond the scope of this
study.
Results
Reimbursement is both highly heterogeneous across
countries and quickly developing at the same time. Figure
1 displays a set of descriptors that serve best to character-
ize coverage decision-making procedures in international
comparison. These descriptors can be seen as crucial steps
in the value chain between market authorization and dif-
fusion: (1) after market authorization, a company's prod-
uct enters the scope of a healthcare payer. (2) The decision
maker now has to decide whether, at what cost and under
which conditions to cover the technology. As there may be
different deciding bodies (e.g. on a national or regional
level), the decision process needs to be considered rele-
vant by one specific deciding body before this body's deci-
sion process starts. (3) The decision maker typically
applies some method of assessing the technology under
investigation (e.g. formal reviewing the literature or ask-
ing for expert opinion). (4) The information provided by
the assessment feeds into an appraisal of whether or not
to cover a technology should be covered. (5) After grant-
ing coverage, a reimbursement rate needs to be fixed. (6)
Besides funding a technology's use, the payer may use
other options to exert influence on service provision, e.g.
by requiring pre-authorization for expensive technolo-
gies. (7) Typically, there are different stakeholders (e.g.
doctors or patient groups) to the decision who may be
involved formally or informally in the decision process.
(8) The decision maker may provide information about
the decision process or its outcome during different steps
of the decision process. There may be cases where some or
even all of these steps are taken simultaneously.
These decisions about coverage, reimbursement and care
management will then have a strong impact on the tech-
nology's use in health care. Information derived from this
use may provide feedback to the different stages of this
development: off-label use by doctors may provide infor-
mation for product development on new target markets
[17]; post-approval data may be used for regulatory sur-
veillance [18]; and it may be used to inform or re-start
coverage and reimbursement decisions – particularly in
the case of coverage with evidence development [19-21].
In the course of the product's life cycle, the decisions
involved with proceeding become increasingly heteroge-
neous: while for many products, market authorization is
granted on a supra-national or at least a national level,
there are usually several healthcare payers per country.
Within the organization of one payer, there can be more
than one decision process; e.g. if decisions about new
drugs differ from decisions about other technologies or if
a formal process is only triggered in case of high budget
impact. The heterogeneity further increases over the
course of technology diffusion – eventually, decisions of
adopting the new technology are made on the level of sin-
gle healthcare providers or even single doctors. This
increasing heterogeneity of decisions is shown in Figure 2.
For an overview of procedures for coverage decision-mak-
ing in the case of technologies like ACI, see Table 1 below.
In the following, further details on the individual steps in
the coverage process are provided.
Payer
Besides out-of-pocket payments, healthcare financing can
for example be provided by national and local health serv-
ices, statutory social insurance systems, private insurance
companies, employer-based insurance or integrated serv-
ice delivery systems with insurance function [22]. The rel-
evance of different types of healthcare payers differs
The fourth hurdle within the process of translational medicine Figure 1
The fourth hurdle within the process of translational medicine.
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substantially across healthcare systems. Seen from an eco-
nomic perspective, healthcare payments in England are
dominated by one central payer. Also in Germany, the
sickness funds within the statutory health insurance sys-
tem dominate health care financing. For the US healthcare
sector, a variety of financing organizations have to be
taken into account. To capture the whole relevant market,
it is important for a life sciences company to consider all
relevant payers for the target healthcare system.
To arrive at an estimate of the relevance of a product's
market size covered by the healthcare payer, the number
of covered individuals and the types of reimbursed serv-
ices are of interest to a company. As an example, the Ger-
man statutory health insurance covers about 90% of the
German population. In 2007, its total expenses for health
services amounted to £144 billion [23]. While the Ger-
man statutory health insurance covers individuals at all
ages, Medicare in the USA mainly covers the elderly, at a
total amount of approximately US$300 billion in 2004.
To achieve coverage of technologies primarily for young
patients, other payers like the BCBS companies would
therefore have to be targeted by a life sciences company.
Trigger
To be able to tailor its product to the purchaser's prefer-
ences, it is relevant for a life sciences company to know
who is going to make the decision to finance its product.
Coverage decisions are frequently associated with
national institutions under the spotlights of politics and
the media. Yet due to limited capacities of reviewing bod-
ies, only a small portion of novel technologies is subjected
to the resource-consuming formal procedures of national
bodies. The vast majority of decisions are usually made at
the meso-level of regions or healthcare organizations such
as primary care trusts in England or providers' "local cov-
erage determinations" for Medicare in the US. Usually,
decisions at the meso-level are far less formalized and thus
less suitable for systematic analysis of published docu-
ments [24].
Knowing the trigger for a decision-maker's formal evalua-
tion process is, therefore, relevant to determine whether a
decision-maker's formal criteria can be expected to be
applied at all. Various systems for prioritizing technolo-
gies for further investigation can be found across decision
makers. Criteria that new technologies have to fulfil to
become subject of a formal appraisal process include
high-budget impact or disagreement on the technology's
effectiveness [25]. In the case of NICE, only technologies
with a significant health benefit, impact on other health-
related government policies and/or impact on NHS
resources are assessed, where the institute is likely to be
able to add value by issuing national guidance.
For Germany, primarily the procedure of initiating an
appraisal is made explicit: the committee's directives on
evaluating technologies only determine the parties
authorized to initiate an assessment [26]. Ambulatory
treatments are only reimbursed upon explicit acceptance
by the Committee – thus, every novel treatment has to
pass the committee. The opposite is the case for in-patient
services: Here, any novel procedure is covered implicitly
within the DRG framework unless it is explicitly excluded
by the decision-maker.
Coverage decisions require medical, economic and legal
expertise. Thus, they are usually made by interdisciplinary
committees. For the German statutory health insurance,
decisions are made on behalf of both the Federal Associa-
tions of Sickness Fund Physicians or the German Hospital
Association and the Federal Associations of Sickness
Funds by the G-BA [27]. For the English National Health
Service, NICE commissions appraisal committees consist-
Increasing heterogeneity of decisions in the process of translational medicine Figure 2
Increasing heterogeneity of decisions in the process of translational medicine.
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Table 1: Overview of the fourth hurdle for ACI
Payer Germany, Statutory 
Health Insurance
England, National 
Health Service
USA, Medicare USA, Blue Cross 
Blue Shield
Trigger of coverage 
decisions
All hospital services are 
covered unless excluded 
explicitly. Evaluation upon 
request of entitled parties 
(no manufacturers)
All ambulatory services are 
excluded unless included 
explicitly. Evaluation upon 
request of entitled parties 
(no manufacturers)
Technologies with significant 
health benefits, social/political 
effects, impact on NHS 
resources and added value 
through guidance by NICE
Initiation of National 
Coverage Determination: 
Internally by CMS, external 
request by interested or 
aggrieved parties. Only 
services with considerable 
impact on the program are 
evaluated
Initiation of Local Coverage 
Determination: Internally by 
the contractor in case of need 
and in the absence of a NCD
Initiation on company-level, 
e.g. with Anthem internally by 
Medical Directors; externally 
by physicians, manufacturers, 
HTA organizations
Deciding committee G-BA, Commission for 
hospital services [27]
G-BA, Commission for 
ambulatory services [27]
Independent Appraisal 
Committee on behalf of NICE 
[28]
CMS [78]C o n t r a c t o r ' s  M e d i c a l  
Director [78]
Mostly committee or Medical 
Director
Assessment Review of evidence of medical benefit in patient-relevant 
endpoints [15,30,35,42]; HTA potentially by the Institute of 
Quality and Efficiency in Health Care
Cost-utility model based on 
all evidence available by 
contracted technology 
assessment team; threshold 
area about £20–30.000/
QALY) [79]
Review of evidence of medical 
benefit; HTA potentially by 
Agency for Healthcare 
Research and Quality; by 
other HTA institution; or by 
Medicare Coverage Advisory 
Committee [8]
Review of evidence of medical 
benefit; HTA potentially by 
external institution [8]
Review of evidence of medical 
benefit; HTA potentially by 
Technology Evaluation 
Committee or other HTA 
institution [9]
Criteria for Appraisal Expedience, necessity and efficiency Effectiveness and cost-
effectiveness
Reasonable and necessary Reasonable and necessary Medically necessary 
(Approval, evidence for net 
health benefits, as beneficial as 
established alternatives, 
attainable outside 
investigational settings)
Reimbursement In-patient: DRGs Out-patient: Fee for service Global budgets for PCTs; 
DRGs paid by PCTs for 
hospital services
DRGs/Fee-for-service/budgets (MCOs)
Management of service 
provision
e.g. quality assessment of doctors e.g. requirement of 
participation in clinical trial
e.g. preauthorization
Participation of company Consideration of written comments Comments about open issues, 
HTAs and provisional 
decision; submission of 
model, appeal possible
Defined periods for 
comments of all interested 
parties
Heterogeneous; contractors 
are required to permit 
participation
Heterogeneous; mainly 
participation of medical 
experts
Publication Amongst others, current 
open issues, assessment 
reports and decisions are 
available through the internet
Process, assessment and 
appraisal available through the 
internet
Current open issues and 
decisions are available 
through the internet
Written communication in 
the jurisdiction of the 
contractor; also available 
through the internet
Heterogeneous; medical 
policies often available 
through the internet
Abbreviations: CMS Centers for Medicare and Medicaid Services; DRG Diagnosis-Related Group; G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee); HTA Health Technology 
Assessment; MCO Managed Care Organization; NICE National Institute of Health and Clinical Excellence; PCT Primary Care Trust;BMC Health Services Research 2008, 8:194 http://www.biomedcentral.com/1472-6963/8/194
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ing representatives of relevant stakeholders in the health
care system to provide guidance on the technology under
investigation [28]. For the decisions on ACI made in the
USA, the insurers' medical directors played a major role.
Frequently, they rely on the support of an interdiscipli-
nary committee of researchers and other independent
experts.
Assessment
Typically, new technologies undergo some form of assess-
ment of patient benefit or cost-effectiveness prior to the
decision. These assessments frequently differ from those
used for market approval [29]. In the case of formalized
decisions, they often are commissioned out to assessment
teams or institutions.
How patient benefit should be established is ambiguous
and a topic of persistent controversy, particularly with
regard to the use of surrogate endpoints in health-impact
measurement and the appropriateness of measurement
tools for health-related quality of life [30]. Another point
of continual debate is the grading of quality of evidence.
Evidence-based medicine advocates the use of high-qual-
ity clinical evidence [31]; however, if studies are available,
their results tend to reflect a technology's efficacy, while
the coverage decision-makers are interested in its "real
world" effectiveness in day-to-day medicine. The empha-
sis of health technology assessments is usually placed on
patient-relevant therapy endpoints compared with the
current standard of care – as opposed to the frequently
used intermediate endpoints in placebo-controlled trials
for market approval. Frequently, the full consideration of
patient-relevant health outcomes as, for example, changes
in residual life expectancy, is beyond the scope of clinical
studies. Therefore, decision-makers have to specify their
attitudes towards modelling approaches.
Economic evaluations add the issue of value for money
and include the costs of a treatment, which implies the
assessment of the cost of the respective treatment strategy
as a whole, not only the product price. Depending on the
type of outcome compared with the costs, different types
of studies can be distinguished: cost-benefit analyses
measure benefit in terms of willingness to pay; cost-utility
analysis use utility values represented by quality-adjusted
life years; and cost-effectiveness analyses compare the
additional costs associated with a new treatment with the
additional health benefit in terms of clinical endpoints
[32,33]. A variety of guidelines for economic evaluation
have been developed [34]; open issues include, for exam-
ple, the perspective of the studies or the discount rates for
future costs and effects to be applied.
NICE, for example, uses cost-utility models as the state of
the art to obtain data for a health technology's effective-
ness and cost-effectiveness. Independent academic centres
are commissioned to review the published evidence on
the technology and synthesize this evidence in decision-
analytic models.
The G-BA can commission technology assessments to the
Institute for Quality and Efficiency in Health Care (Insti-
tut für Qualität und Wirtschaftlichkeit im Gesundheits-
wesen, IQWiG). This institute also is involved in the
development of methods for the evaluation. IQWiG holds
a critical attitude towards the use of models and rejected
the use of quality-adjusted life years in its statement of
methods published in December 2006 [35]. In its state-
ment of "Methods for Assessment of the Relation of Ben-
efits to Costs in the German Statutory Health Care
System" published in January 2008, an efficiency frontier
approach to economic evaluation was recommended
[36]. The methods guidance provides little and partially
inconsistent information about the use of decision ana-
lytic modelling for evidence synthesis or QALYs for the
establishment of effectiveness [37]. Also its revised state-
ment of general methods published in May 2008 does not
address the issue of decision-analytic modelling or QALYs
and focuses on the establishment of patient benefit on the
basis of clinical trials [38].
For companies in the Blue Cross and Blue Shield Associa-
tion, the Technology Evaluation Center (TEC) is an
important source of health technology assessment meth-
ods and reports. The use of formal cost-effectiveness anal-
yses has been advocated in the USA [39] and standards for
their use in drug coverage decisions have been proposed
by the American Academy of Managed Care Pharmacy
[40]. Still, their current use in coverage decision-making is
rare and assessment of new technologies is mainly based
on clinical evidence to establish whether a product
improves health outcomes [41].
Appraisal
These assessments feed into an appraisal of the new tech-
nology which may to a large extent be determined by
social legislation. For example, according to Book Five of
the German Social Code, the G-BA is to appraise whether
technologies are "expedient, necessary and efficient" [42].
On behalf of NICE, independent appraisal groups are to
appraise the technology's effectiveness and cost-effective-
ness; guidance for parts of the additional principles and
reflections to account for in the appraisal is provided in a
document on social value judgements for NICE appraisals
[43-45]. Medicare is to assess whether the technologies are
reasonable and necessary; and the BCBS companies are to
assess medical necessity [46].
In the case of ACI, the decisions differed across deciding
bodies. For example, the G-BA did not reject in-patientBMC Health Services Research 2008, 8:194 http://www.biomedcentral.com/1472-6963/8/194
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treatment with ACI in knee joints so that it is covered by
the statutory health insurance [47]. NICE rejected general
coverage. However, ACI is being funded as part of a large
multi-centre clinical trial to collect further effectiveness
data [48]. In the USA, one local coverage determination
for Medicare denied coverage of ACI [8]. Among the Blue
Cross Blue Shield companies, medical policies regarding
ACI differed considerably [9].
Reimbursement
Market access in terms of coverage may not be sufficient
to allow for appropriate funding of a novel healthcare
technology. The determination of the level of funding
provided by third-party payers is frequently a distinct step,
which may involve different decision-making bodies. In
some cases (e.g. for new, innovative drugs in Germany),
the price requested by the manufacturer is reimbursed
directly. Alternatively, insurers may enter into price nego-
tiations with manufacturers as occurs for new drugs in the
USA. Besides the amount reimbursed, technical require-
ments for reimbursement need to be established, e.g. new
codes for procedures in fee schedules [49].
Reimbursement can take the form of global budgets, sala-
ries, capitation, case-based payments, fee-for-service or
mixed schedules [22]. It has been shown that technology
diffusion rates are higher in the case of retrospective fee-
for-service reimbursement than for prospective global
budgets [50,51].
In a hospital setting, where products like ACI are typically
applied, reimbursement is usually in diagnosis-related
groups (DRGs) [52]. These groups have been introduced
recently in Germany, as well as in the UK. Here, innova-
tions that are cost-saving from the hospital's perspective
have a major competitive advantage. For cost-increasing
innovation, the application of DRGs to higher expenses
may be time-consuming or may fail despite formal cover-
age of the procedure.
Reimbursement mechanisms can be explicitly designed to
accelerate or block the adoption of certain new and more
expensive technologies. An example for drug reimburse-
ment provides reimbursement of reference prices instead
of manufacturer prices [53]. Examples of mechanisms to
accelerate technology adoption in the case of DRG pay-
ments are additional reimbursement components for
selected technologies [54].
Management
Reimbursement of a new healthcare technology may
come along with specified rules for service provision or
quality controls. In general, approaches to connect financ-
ing of healthcare to service provision have been termed
"managed care" [55]. Examples of tools of managed care
are utilization review or standard treatment protocols
[22,55]. The stronger this connection, the better the payer
can exert influence on the diffusion of new technologies
[56,57].
Managed care has played a particularly important role in
the USA: most payers offer managed care products. Never-
theless, the number of fully integrated HMO plans has
decreased considerably since the end of the nineties [58];
insurance products with traditional fee-for-service pay-
ment are available. A tool used frequently by private
health insurance in the USA to control service provision is
preauthorization, which is especially common with new
therapies like tissue-engineering products.
Coverage of new technologies can also be linked with
requirements for collecting further data on the technol-
ogy's effectiveness or cost-effectiveness. This so-called
"coverage with evidence development" (CED) balances
the aim of offering patients promising new health tech-
nologies with the demands for prudent use of resources
and the principled arguments that coverage should be
based on solid evidence of clinical effectiveness [19,20].
Value of information analysis provides tools to substanti-
ate the decision of whether and which further evidence
should be collected to confirm coverage decisions [59]. In
the case of ACI, CED has been applied by NICE.
Participation
Reimbursement decisions are made in the context of a
variety of stakeholders' interests [60]. Besides information
rights, the major stakeholders may also be involved
actively in the decision-making process. The company's
formal role in coverage determination procedures may,
for example, be the option to initiate a coverage decision,
to provide additional information, to participate in public
hearings or to appeal within a fixed period.
The decision-making process by NICE is exceptional in
terms of stakeholder participation: a manufacturer is
offered the status of formal consultee in the appraisal
process. This implies that he/she can participate in the
"scoping" of the assessment, comment on various docu-
ments, submit a report on clinical and cost-effectiveness
and appeal against the final appraisal. In decisions by the
German G-BA, stakeholder participation beyond doctors
and statutory health insurance funds is mainly reduced to
comments from medical experts, self-help groups and
patient organizations, as well as from umbrella associa-
tions of manufacturers.
Publication
Usually, national bodies publish decision memorandums
on websites or in official government documents. In the
case of national decisions, published material can go farBMC Health Services Research 2008, 8:194 http://www.biomedcentral.com/1472-6963/8/194
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beyond the decisions themselves. Frequently, decision
bodies are additionally obliged to meet standards of pro-
cedural transparency and to publish themes of future con-
sultations or documents from ongoing processes.
Information on decisions and their rationale is less acces-
sible for decisions at the micro- or meso-level. As far as
they are available, these publications provide valuable
information for companies both on how to learn best to
fulfil requirements for reimbursement and how to keep
trace of their competitors.
The English NICE has high standards regarding transpar-
ency in decision-making: not only the appraisals and the
evidence they are based on, but also a number of docu-
ments in the decision-making process are published
online. The German G-BA publishes their decisions and
the related health technology assessment reports on their
website [see e.g. [61]]. The Centers for Medicare and Med-
icaid services established a database, from which both
local and national coverage determinations are accessible
http://www.cms.hhs.gov/MCD/search.asp.
Table 1 provides an example for a comparative snapshot
of the fourth hurdle in Germany, England and the USA. It
displays the decision processes including examples of
management of services provision for the innovative med-
ical procedure of ACI.
Discussion
This study presents a simple framework for monitoring
fourth hurdle procedures, which consists of eight key
steps. Compared with alternative approaches, this frame-
work allows for easy monitoring of these key steps in the
process of coverage determination and for easy communi-
cation to decision-makers in research and development.
It additionally allows for a comparison of very different
processes, e.g. those in English primary care trusts. Even
though the majority of coverage decisions are made at this
sub-national level, these processes are frequently ignored
by the literature.
The framework is best suited to describe formal stages of
coverage decisions, based on published documents. Yet
usually, health policy decisions are subject to diverse and
potentially conflicting political interests [11,24,60,62],
and stakeholders like doctors' associations, patient groups
or industry representatives may be involved in an infor-
mal manner. Frequently, the decisions are, at least to
some extent, affected by informal considerations [63] and
based on colloquial rather than scientific evidence [64].
Especially for the stages "Trigger", "Appraisal" and "Partic-
ipation", studies of fourth hurdle procedures can there-
fore benefit from an inclusion of both formal and
informal elements. A substantial part of the variance of
health technology decision-making, and thus the proba-
bility of success for companies, will remain unexplained
by an analysis of overt documents and decision criteria
only.
While, on the one hand, the framework is primarily for a
descriptive analysis of fourth hurdle procedures, it can
also serve as a starting point for normative analysis. Dan-
iels and Sabin propose four criteria for coverage decision
procedures in order to meet the standard of "accountabil-
ity for reasonableness" [65]: (1) Decisions regarding cov-
erage for new technologies and their rationales must be
publicly accessible (publicity condition); (2) These
rationales must rest on evidence, reasons, and principles
that all fair-minded parties can agree are relevant to decid-
ing how to meet the diverse needs of a covered population
under necessary resource constraints (relevance condi-
tion); (3) There must be a mechanism for challenge and
dispute resolution regarding limit-setting decisions
(appeals condition); and (4) There is regulation of the
process to ensure that the first three conditions are met
(enforcement condition). Applying the framework pre-
sented in this study to coverage decision processes addi-
tionally delivers information on their accountability for
reasonableness, because it includes descriptive informa-
tion for criteria (1)–(3) as proposed by Daniels and Sabin.
Relation of process and outcome
The coverage decisions for the reference case study are het-
erogeneous: Coverage is provided by the German statu-
tory health insurance for hospital care and by a number of
private payers in the USA if certain criteria are met. Cover-
age was declined by NICE (yet the development of further
evidence is supported), as well as by the one Medicare
local coverage determination.
One major reason for this heterogeneity may be the
ambiguous evidence both for the effectiveness and cost-
effectiveness of ACI: there are studies that suggest ACI is
effective, but the long-term effectiveness and cost-effec-
tiveness remain to be established [10]. The differences
may also be explained partly by the payers' scope: as a
major potential benefit of ACI is presumed to be sustain-
ability as compared with implants, it is of higher relevance
for younger patients than for individuals over the age of
65. Therefore, Medicare would be more likely to decline
coverage, than would benefit schemes for younger
patients.
Interestingly, the German G-BA arrived at different con-
clusions for different conditions: while coverage for ACI
in finger and shoulder joints was denied, the coverage
decision for ACI in knee joints was postponed until 2014,
with no conclusive evidence of long-term effectiveness for
either condition. The explanatory statement justified thisBMC Health Services Research 2008, 8:194 http://www.biomedcentral.com/1472-6963/8/194
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decision according to anticipated new evidence, particu-
larly from studies in England. This can be taken as an
example of the substantial amount of unexplained vari-
ance in coverage decisions, yet may also partially be
explained by cooperation among coverage decision-mak-
ers; apparently, the G-BA is waiting for the results of fur-
ther clinical studies conducted on behalf of NICE.
How to pave the way from bench to bedside
To pave the way for a research project from bench to bed-
side, project managers should prepare for the stages
through which a novel technology will have to pass before
being applied in healthcare. This framework provides
background information and can help identifying impor-
tant issues to address. These include, for example, which
decision procedure is likely to be triggered by the product.
If formal decisions on a macro-level are likely, clinical tri-
als should be designed to include the endpoints and
potentially the treatment alternatives requested by the rel-
evant fourth hurdle processes.
The level of detail in which these questions can be
answered will depend on the stage of project development
[66]. Early in research, it may be sufficient to do an explor-
ative search of HTA reports for potential target conditions.
This provides a first overview of potential medical need,
practice patterns and competitors. Closer to the clinical
trial stage, it may be worthwhile to develop early health
technology assessments. A number of analytical tools are
available for purposes like early market assessment, R&D
portfolio management and first estimations of pricing and
reimbursement scenarios. Nevertheless, high uncertainty
of clinical and economic data in early stages restricts the
validity of modelling results [67,68]. As soon as sufficient
clinical data are available, formal health economic mod-
els can be used to establish information needs for further
clinical trials or scenarios for cost-effective pricing strate-
gies.
Limitations of this analysis
Any overview of coverage decisions can only be a snap-
shot, as institutions and requirements for coverage of new
medical technologies are subject to frequent, considerable
changes. This is illustrated by recent reforms in all coun-
tries included in this review, e.g. the introduction of for-
mal cost-effectiveness analysis for novel drugs in Germany
which was passed in parliament in February 2007. In June
2008, the methods of cost-effectiveness analysis were still
subject to debate [36]. Therefore, the results presented in
this article's case study, as well as for any company's target
health technologies, warrant regular updating.
The US healthcare system is highly heterogeneous and
hosts a multitude of payers, many of which have different
processes and requirements. Even though the case study
presented above investigated major players, findings can
hardly be generalized.
Besides the processes described in Table 1 of this study,
further decision processes exist – in the case of Germany
for example for ambulatory drug reimbursement or dental
care; in England for example the procedures within pri-
mary care trusts. Even if the framework is generic, the
overview in Table 1 had to focus on those processes which
made decisions about ACI. It therefore does not provide a
conclusive overview but an example of fourth hurdle
processes.
The EMEA and the FDA have different practices for licens-
ing [69,70], and for other technologies like medical prod-
ucts other procedures and criteria for market approval
exist [71]. More rigorous licensing practices may filter out
technologies that otherwise have to be assessed by fourth
hurdle institutions. Therefore, these procedures which are
not in the scope of this study have an influence on proce-
dures for coverage and reimbursement.
In general, the procedures involved in the translation of
clinical research from bench to bedside are internationally
very heterogeneous and complex. Therefore, any simple
framework can be claimed to lead to over-simplification
and there are research questions for which the framework
is not the best choice. For a detailed institutional analysis
of coverage decision-makers, the framework developed by
Hutton and colleagues would be better recommended
because it can provide more precise answers [6]. The
framework also has its limitations if rather than one spe-
cific technology, an overview of coverage of very different
types of technologies, e.g. within one country, is to be pro-
vided. Within this process-oriented framework, these
decisions would all be described as a multitude of single
decision processes. This might jeopardize the framework's
simplicity. It is, therefore, better suited for a technology-
specific description of the fourth hurdle – which corre-
sponds with the need of a project manager to have the
technology life cycle of a single project in mind, rather
than a country's system for coverage determination. To
describe entitlements to health benefits for a country, an
approach like the one chosen by the Health Basket Project
may be more appropriate [42].
The diffusion of health technology is a dynamic process
between patients, physicians, hospitals, healthcare sys-
tems and technology. Apart from a product's effectiveness
or cost-effectiveness, important impact factors in this
process include purchasing power in the target country
[50] or commercial marketing efforts [72,73]. Some of
these impact factors will also appear in an application of
this framework, e.g. as informal decision criteria (e.g.
affordability) or informal participation (e.g. influence byBMC Health Services Research 2008, 8:194 http://www.biomedcentral.com/1472-6963/8/194
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the industry). Nevertheless, researchers interested in that
area should draw upon models and approaches devel-
oped in the literature on health technology diffusion
[50,72-74].
Conclusion
Implications for researchers and life sciences companies
All over the world coverage decision-makers are develop-
ing procedures to prioritize healthcare spending. Project
managers involved in the translation of research projects
from bench to bedside should keep track of the relevant
fourth hurdle procedures in their target countries as part
of their marketing activities. The framework presented
above provides a tool to describe and compare these pro-
cedures in a transparent and manageable manner.
The focus of a decision-maker's interest is the evidence-
based establishment of a technology's effectiveness in
terms of patient-relevant endpoints. Of the three coun-
tries under investigation in the case study, the use of for-
mal cost-effectiveness analysis was to a large extent
restricted to NICE in England – yet due to increasing need
for prioritization as a result of escalating healthcare costs,
the high international perception of NICE and the evolv-
ing use of formal cost-effectiveness analysis for drug treat-
ments [4,11,39,75], it can be assumed that its importance
will increase in future for other healthcare technologies.
Life sciences companies should include final health out-
comes in their clinical trials for market approval, to pro-
vide information on patient benefit in order to achieve
coverage. They should additionally collect resource con-
sumption data, so that they can provide health economic
evidence if required.
Implications for policy-makers
As shown in Figure 2, project managers are confronted
with a variety of heterogeneous fourth hurdle procedures
that lead to different outcomes. To enhance translational
medicine, it would be desirable to increase the consist-
ency of fourth hurdle procedures across payers and
healthcare systems.
It has been reported that the criteria for establishment of
effectiveness and value for money are not always applied
consistently [15,76]: decisions may be inconsistent with
stated requirements, as for ACI-coverage in Germany, or
they may be inconsistent between different deciding bod-
ies, as for ACI coverage by Blue Cross Blue Shield compa-
nies in the USA. It is important that efforts to standardize
fourth hurdle procedures do enforce, rather than jeopard-
ize, their accountability for reasonableness [77], and lead
to the adoption of those health services that are most
desired by patients and the population.
To enhance the translation of research findings, it would
be desirable if institutions for research funding would
increase awareness of later stages in the project develop-
ment process. This could be conducted, for example, if as
a part of advertisements for research opportunities, infor-
mation on targeted markets and potential reimbursement
strategies was requested.
Implications for further research
There are a variety of open research questions on the dif-
ferent process steps. The framework presented here can
assist researchers in identifying and distinguishing differ-
ent areas of research at the important intersection of trans-
lational medicine and health services research. Two major
areas of further research on the whole process of transla-
tion should be addressed: first, fourth hurdle institutions
have been subject to continual reform. Thus, the frame-
work presented above should be applied on a regular
basis to keep track of changing conditions of market entry
and diffusion. The framework was applied only to one
technology and a limited number of decision-makers in
three countries. It would, therefore, be of additional inter-
est to include further decision-makers and reference tech-
nologies in future analysis. Second, coverage is a crucial
target for the marketing activities of life sciences compa-
nies. It would be of value to develop further guidance on
how requirements for coverage can be integrated into
innovation management in a more systematic manner.
Given the escalating healthcare costs in industrialized
countries and the rising importance of fourth hurdle pro-
cedures to prioritize healthcare resources [4], it can be
expected that the need for tools and guidance is likely to
grow in the future.
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